Breathing Easier: Key Takeaways from the GINA 2026 Global Strategy for Asthma Management

1. Introduction: The Global Weight of Asthma

Asthma is not merely a chronic condition; it is a global health crisis that remains unacceptably burdensome. Currently, approximately 300 million people live with the disease worldwide, and tragically, asthma continues to claim roughly 1,000 lives every single day. The vast majority of these deaths occur in low- and middle-income countries, highlighting a preventable failure in global health equity.

The GINA 2026 update represents a sophisticated, evidence-based evolution in our approach to this heterogeneous disease. Its core purpose is to provide healthcare providers with a streamlined strategy to reduce morbidity and mortality through highly personalized care. By bridging the gap between clinical research and bedside practice, GINA 2026 aims to ensure that every patient—regardless of geography—receives treatment that addresses the underlying inflammatory nature of their condition.

2. The 2026 Paradigm Shift: Safety Over Speed

The 2026 strategy introduces several high-impact changes that prioritize patient safety and standardized emergency response. Clinicians should take note of the following updates:

• Four New Management Flowcharts: GINA has introduced dedicated clinical pathways to ensure standardized care across all ages and settings. These cover: (1) Adults/Adolescents and Children 6–11 in Primary Care; (2) Adults/Adolescents and Children 6–11 in Acute Care/ED; (3) Children $\le$ 5 in Primary Care; and (4) Children $\le$ 5 in Acute Care/ED.
• Revised Oxygen Thresholds: In a move toward a "less is more" approach to prevent over-oxygenation, supplemental oxygen is now only recommended if saturation falls below 92%. The target saturation is 95% for adults and children over six, and $\ge$ 92% for children aged five and younger.
• The SABA Toxicity Warning: We are seeing increased evidence of over-treatment during acute episodes. Excessive short-acting beta2-agonist (SABA) use can lead to lactic acidosis and compensatory hyperventilation, which may be misinterpreted as worsening asthma. Crucially, all suspension pMDIs (like salbutamol) must be shaken immediately before each actuation. Failing to do so can result in the administration of inadvertent ultra-high doses from a new inhaler or insufficient doses from an older one.
• Advanced Assessment Tools: Clinicians should adopt the Chronic Airways Assessment Test (CAAT) for adults to evaluate health status, and the Pediatric Asthma Impairment and Risk Questionnaire (Peds-AIRQ) for children aged 5–11 to better gauge future risk.

3. Modern Treatment Paradigms: Track 1 vs. Track 2

GINA 2026 continues to refine the two-track approach for adults and adolescents, placing a heavy emphasis on the safety profile of anti-inflammatory relievers (AIR).

Feature	Track 1 (Preferred)	Track 2 (Alternative)
Reliever Medication	ICS-formoterol (Anti-inflammatory reliever or AIR)	SABA or ICS-SABA
Maintenance Medication	Uses the same ICS-formoterol inhaler daily (MART) or as-needed (AIR).	Separate ICS-containing maintenance inhaler is mandatory.
Nomenclature	AIR: As-needed use only. MART: Maintenance and Reliever Therapy using one device.	Alternative: For patients where Track 1 is not possible or appropriate.
Clinical Rationale	Prevents "selective non-adherence"; treats inflammation with every rescue dose.	Required for patients stable on SABA relievers who are adherent to maintenance ICS.

Synthesis of Recent Evidence: Track 1 remains the preferred approach because it substantially reduces the risk of severe exacerbations and limits the carbon footprint of respiratory care. However, Track 2 has seen a significant evidence boost: the BATURA study demonstrated that using as-needed ICS-SABA in Track 2 Step 1 reduces the risk of severe exacerbations by almost 50% compared to SABA alone. This confirms that even in alternative tracks, SABA-only therapy is no longer the standard of care.

4. Confirming the Diagnosis: Test Before Treating

Confirming the diagnosis of asthma via objective testing is essential to avoid misdiagnosis and over-treatment. One-third of adults with a previous asthma diagnosis cannot have it confirmed upon repeat testing; some of these patients actually suffer from serious cardiorespiratory conditions.

Criteria for Initial Diagnosis: To confirm asthma in adults and children (6–17), clinicians must document a history of variable respiratory symptoms and confirmed variable expiratory airflow:

1. Adults: An increase in FEV1 of $\ge$ 12% and $\ge$ 200 mL after bronchodilator use. Note: An increase of $\ge$ 15% and $\ge$ 400 mL provides "greater confidence" in the diagnosis.
2. Children: An increase in FEV1 of $\ge$ 12% predicted.
3. Variability: Excessive diurnal PEF variability (>10% in adults; >13% in children).
4. Biomarkers: Elevated FeNO (>50 ppb in adults) or blood eosinophils support a "Type 2" phenotype but do not rule out asthma if levels are low.

Pro-Tip: The Diagnostic Gold Standard Always perform lung function testing before initiating ICS-containing treatment. ICS rapidly improves symptoms and reduces variability, which can mask the objective evidence needed to confirm a diagnosis later. If testing is normal but symptoms are typical, consider repeating the test during a symptomatic period or checking for Type 2 biomarkers.

5. Addressing Severe Asthma and New Biologic Options

For the small percentage of patients whose asthma remains uncontrolled despite high-dose ICS-LABA, the biologic landscape is expanding rapidly.

New Additions to the Toolkit:

• Depemokimab: A long-acting anti-IL5 (administered every 26 weeks) approved for severe eosinophilic asthma (ages 12+) and adult chronic rhinosinusitis with nasal polyps (CRSwNP).
• Omalizumab-igec: The first biosimilar anti-IgE, providing an equivalent alternative to the original omalizumab.

Biologic Selection Checklist:

• Eligibility: Does the patient meet local regulatory or payer criteria?
• Predictors of Response: Are blood eosinophils or FeNO elevated?
• Comorbidities: Does the patient have CRSwNP or other conditions a specific biologic might treat?
• Patient Preference: Consider the route (SC vs. IV) and frequency (e.g., depemokimab's 26-week dosing).

6. OCS Stewardship: Minimizing the Steroid Burden

Oral corticosteroid (OCS) stewardship is a priority in GINA 2026. The goal is to minimize cumulative OCS exposure to prevent long-term adverse effects like osteoporosis, diabetes, and cataracts.

Clinicians must optimize inhaled therapy (prioritizing Track 1) and utilize biologics early when indicated. Stewardship involves monitoring cumulative OCS use and implementing non-pharmacologic techniques during respiratory infections to manage symptoms without reflexively reaching for a steroid burst. Maintenance OCS should only be considered as a last resort after all other therapeutic avenues are exhausted.

7. Global Access and Sustainability: World Asthma Day 2026

The theme for World Asthma Day 2026—"Access to anti-inflammatory inhalers for everyone"—highlights the urgent need for equitable medication pricing, especially in low-resource settings. GINA is currently working toward a World Health Assembly Resolution to improve access to inhaled medicines globally.

Simultaneously, we must address the environmental impact of asthma care. The propellants in pMDIs contribute significantly to the carbon footprint of healthcare. GINA supports the use of dry-powder inhalers (DPIs) where clinically appropriate, as they offer a substantial reduction in environmental impact while providing the same life-saving anti-inflammatory benefits.

8. Conclusion: Actionable Takeaways for the Clinic

The GINA 2026 strategy provides a clear, safety-first roadmap for contemporary asthma management.

Top 5 Takeaways for 2026:

1. Prefer Track 1: Use ICS-formoterol as the reliever across all steps to treat inflammation at the moment of symptoms.
2. Test First: Secure an objective diagnosis via spirometry or PEF before starting long-term ICS.
3. Modernize Acute Care: Utilize the four new 2026 flowcharts for standardized exacerbation management.
4. Respect the 92% Threshold: Use supplemental oxygen judiciously to avoid the risks of over-oxygenation.
5. Practice OCS Stewardship: Monitor cumulative doses and use non-pharmacologic strategies to minimize the steroid burden.

For the full report and clinical resources, visit www.ginasthma.org.